Pharmacy spending (more from Desktop Resource, Feb. 2008)

Amongst a few recommendations, Commonweath is encouraging how and how much we as payers, providers and consumers pay for primary care.

The senior vice president of health services and chief medical officer at Independence Blue Cross in Philadelphia discusses the spotlight that the COVID-19 pandemic put on behavioral health and Independence's integration of behavioral health into its coverage and care management in this month's episode of “What's on Your Mind?" podcast.

The Academy of Managed Care Pharmacy is throwing its support behind federal legislation that would create a Medicare benefit category for prescription digital therapeutics.

Briana Contreras, an editor of Managed Healthcare Executive, chats with Bronwyn Spira, CEO and founder of Force Therapeutics, in this week's episode about CMS' new CPT codes that were introduced in 2022.

Although it’s not likely to pass, at least not this year, opponents say the proposal is already accelerating the spread of false claims and sowing distrust of physicians.

Hemgenix for hemophilia B is priced to cost $3.5 million per treatment. Roctavian for hemophilia A may be approved by the FDA in July and is likely to be priced to cost between $2 million and $3 million per treatment.